Industry News
4DMT Publishes Preclinical Data Highlighting the Potential of the Therapeutic Vector Evolution (TVE) Platform

4D Molecular Therapeutics (4DMT) has announced the publication of preclinical data underscoring the ...

read more
4DMT Publishes Preclinical Data Highlighting the Potential of the Therapeutic Vector Evolution (TVE) Platform
December 23, 2024
Sepul Bio Doses First Patient in Phase 2b Trial of Ultevursen for USH2A-Associated Retinitis Pigmentosa

Sepul Bio has announced the dosing of the first patient in the LUNA clinical study, a Phase 2b trial...

read more
Sepul Bio Doses First Patient in Phase 2b Trial of Ultevursen for USH2A-Associated Retinitis Pigmentosa
December 20, 2024
Opus Genetics Receives FDA SPA Agreement for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Opus Genetics has announced a key regulatory milestone, securing a Special Protocol Assessment (SPA)...

read more
Opus Genetics Receives FDA SPA Agreement for Phase 3 Trial of APX3330 in Diabetic Retinopathy
December 20, 2024
Regeneron’s Aflibercept 8mg Injection Meets Primary Endpoint in Phase 3 QUASAR Trial for Retinal Vein Occlusion

Regeneron Pharmaceuticals has announced that its Phase 3 QUASAR trial evaluating EYLEA HD (afliberce...

read more
Regeneron’s Aflibercept 8mg Injection Meets Primary Endpoint in Phase 3 QUASAR Trial for Retinal Vein Occlusion
December 19, 2024
Aurion Biotech Announces Positive Phase 1/2 Results for AURN001 in Corneal Edema Treatment

Aurion Biotech has released topline data from its Phase 1/2 clinical trial (CLARA), evaluating AURN0...

read more
Aurion Biotech Announces Positive Phase 1/2 Results for AURN001 in Corneal Edema Treatment
December 19, 2024
FDA Clears ViGeneron’s IND for VG801 Gene Therapy to Treat Stargardt Disease and ABCA4-Linked Retinal Dystrophies

FDA has cleared the investigational new drug (IND) application for VG801, ViGeneron’s novel gene the...

read more
FDA Clears ViGeneron’s IND for VG801 Gene Therapy to Treat Stargardt Disease and ABCA4-Linked Retinal Dystrophies
December 19, 2024
Viridian Announces Positive Topline Results from Phase 3 Veligrotug Trial for Chronic Thyroid Eye Disease

Viridian Therapeutics has announced positive topline results from the Phase 3 THRIVE-2 clinical tria...

read more
Viridian Announces Positive Topline Results from Phase 3 Veligrotug Trial for Chronic Thyroid Eye Disease
December 18, 2024
EMA CHMP Issues Positive Opinion for Aflibercept Biosimilar from Celltrion

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued...

read more
EMA CHMP Issues Positive Opinion for Aflibercept Biosimilar from Celltrion
December 18, 2024
eyeDNA Therapeutics Receives FDA Rare Pediatric Disease Designation for HORA-PDE6b

eyeDNA Therapeutics, a newly created subsidiary of Coave Therapeutics (‘Coave’), has announced that ...

read more
eyeDNA Therapeutics Receives FDA Rare Pediatric Disease Designation for HORA-PDE6b
December 18, 2024
Vabysmo Prefilled Syringe Approved in the EU for Retinal Conditions

The European Medicines Agency (EMA) has approved Roche's Vabysmo (faricimab) 6.0 mg single-dose pref...

read more
Vabysmo Prefilled Syringe Approved in the EU for Retinal Conditions
December 17, 2024
More